Advising on Pharmaceutical Discovery and Development Strategy

The DDI is staffed by scientists with experience in the pharmaceutical industry at all stages of the drug discovery and development process. Our team advises on how a project should be advanced from the earliest stages of discovery to clinical trial phases and beyond.

Our broad areas of expertise include:

  • Molecular Biology
  • Physiology
  • Medicinal and Process Chemistry
  • Preclinical and Clinical Pharmacology
  • Phase I Clinical Trials Design
  • Pharmaceutical Industry Project Management
  • Interactive Network of Specialized Drug Development Resources

Directing Preclinical Drug Development Activities

The DDI leverages world-class research and drug developement resources at The Ohio State University to advance projects through preclinical development to a clinical trial stage. In cases where the required expertise is not available at Ohio State or accessible within an acceptable development timeframe, the DDI partners with external contract research organizations. The DDI team coordinates and manages all of the necessary early stage drug development activities to ensure a seamless integration of project teams and timely progression of projects.

Managing Intellectual Property

Intellectual property is the tangible, marketable core of every DDI-invested project. Each project has an intellectual property strategy defined before DDI investment. The intellectual property strategy is used to guide the drug development strategy and influences overall portfolio decisions as well. The DDI works closely with licensing officers at the Ohio State Technology Commercialization Office (TCO) to ensure that our invested projects are appropriately disclosed, patented and protected. The DDI and TCO also work together on external partnering, licensing negotiations and contract terms for invested projects.

Developing a Commercialization Strategy

The DDI evaluates the commercial viability of every technology prior to investment and regularly throughout the development process. The DDI recognizes that the pharmaceutical competitive landscape is constantly evolving and that the clinical need for a product may change dramatically within a short time. To understand and respond to changes in commercial potential, the DDI leverages both internal and external resources:

  • The DDI works with the Ohio State Fisher College of Business Technology Entrepreneurship and Commercialization (TEC) Institute to analyze the commercial potential and market position for every invested drug development project. The TEC Institute is experienced in triaging early-stage technologies and developing commercialization strategies. It also coordinates clinician surveys to provide a perspective on the optimal drug profile and any potential barriers to entry for a particular therapy or intervention.
  • The DDI has an advisory board consisting of highly experienced pharmaceutical industry professionals. The board advises on commercial viability or taps into its extensive networks of contacts to provide expert advice when needed.

Partnering and Managing Relationships

The DDI cultivates relationships between internal and external partners, manages alliances and is flexible with the kinds of partnerships and investment models that are developed. Portfolio projects are available for partnering at all stages in the research and development process. The DDI portfolio provides potential partners with innovative de-risked drug candidates with industry-standard data packages and consolidated intellectual property.

Resources

The DDI leverages internal and external resources to accelerate projects. This approach is valuable because it:

  • Ensures no gaps in the early drug development process that would add cost or time
  • Utilizes the right specialist skills at all stages in the early drug development process

Internal Resources


As one of the largest and most research-intensive public universities in the nation, The Ohio State University has a breadth of resources. The Ohio State University Comprehensive Cancer Center (OSUCCC) has five highly interactive cancer research programs involving more than 300 scientists from 12 of the 15 colleges at Ohio State.

In addition to having strong collaborations with researchers, the DDI has also established partnerships with Shared Resources within the OSUCCC that provide:

  • Integrated network of specialized and cost-effective services to facilitate innovative translational science
  • State-of-the-art technology and instrumentation

The DDI works closely with licensing officers at the Ohio State Technology Commercialization Office (TCO) to ensure that our invested drug development projects are appropriately disclosed, patented and protected. The DDI and TCO also work together on external partnering, licensing negotiations and contract terms for invested projects.

The DDI works with the Ohio State Fisher College of Business Technology Entrepreneurship and Commercialization (TEC) Institute to analyze the commercial potential and market position for every invested project.

External Resources


The DDI has established relationships with external contract research organizations that can assist with development activities across the entire drug development process. Some examples of externally sourced capabilities include large-scale chemical synthesis, toxicity studies and counter-screening assessments.

For more information, contact the DDI at ddi@osumc.edu.

Contact the DDI

Email: ddi@osumc.edu
Phone: 614-685-6957 

Support the DDI

Donate Now